Castle Creek Biosciences
Edit info- Founded: 2015
- Location: Exton, PA
- Employee range: 11 - 50
- Clinical stage: Clin3 (fast track)
- Therapy area: Recessive dystrophic epidermolysis bullosa (ODD)
- Drug types: DRM, GEN, PED, RAR, IMM, BON, HEP
- Lead product: D-Fi
- Funding: $112M May 2022; $75M Mar 2020; $71.8M Oct 2018; $48M Oct 2016
castlecreekbio.com linkedin.com job board
Drug notes:
LV-FAH Clin0 hereditary tyrosinemia type 1 (ODD); CCB-003 RD Ehlers-Danlos syndrome; CCB-005 RD Ehlers-Danlos syndrome; CCB-001 RD osteogenesis imperfecta; LV-PAH RD phenylketonuria; undisclosed RD hepatic/metabolic diseases
About:
Castle Creek Biosciences is developing gene therapies for a broad range of genetic diseases. There are many ways to deliver gene therapies: Castle Creek is utilizing a lentiviral (LV) delivery platform to develop and commercialize both ex vivo and in vivo therapies for genetic diseases. Castle Creek’s expertise is in using self-inactivating LVs for ex vivo gene therapy of dystrophic epidermolysis bullosa, a rare skin and connective tissue disorder. Now, Castle Creek is focusing on in vivo gene therapies beginning with inborn errors of metabolism of the liver. With their dual LV vector delivery platform, Castle Creek is establishing their pipeline in pursuit of multiple indications.
Jobs:
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com